ERCC1 (excision repair cross-complementing rodent repair deficiency, complementation group 1), which has been widely reported to increase the proficiency of nucleotide excision repair and augment cisplatin resistance in tumor cells [19], was further examined to confirm CR property in these derived cell lines. Here, ERCC1 is linked to hyperinsulinemic hypoglycemia, familial, 4.